ALK阳性非小细胞肺癌的治疗进展

Progress in the Treatment for ALK-positive Non-small Cell Lung Cancer

目前靶向治疗是针对某些特定分子亚组非小细胞肺癌的有效治疗方法。EML4-ALK是非小细胞肺癌患者中检测到的一种致瘤性融合基因,它的发现促进了临床上对非小细胞肺癌新治疗方法的发展。克唑替尼是一种针对ALK阳性非小细胞肺癌的酪氨酸激酶抑制剂。尽管它在应用中表现出显著的有效性与安全性,但是在治疗过程中仍发生了基因突变而导致其产生耐药性。进一步深入研究这些基因突变对肿瘤治疗方案的选择至关重要。成功地筛选出ALK突变的患者和进一步研发新型靶向药物可更好地促进ALK抑制剂的疗效。

Targeted therapy has emerged as an effective treatment option for certain molecular subsets of advanced non-small cell lung cancer（NSCLC）. EML4-ALK is a fusion-type protein tyrosine kinase in the genome of non-small cell lung cancer（NSCLC）.The discovery of EML4-ALK translocation as an oncogenic driver has led to the development of novel therapies in the clinic. Crizotinib is a tyrosine kinase inhibitor active against ALK-positive NSCLC. Despite its outstanding safety and efficacy,several resistant mutations against crizotinib have been detected in the treatment of NSCLC. Increased understanding of these mutations is essential for tailoring treatment choices to improve outcomes. The second-generation ALK inhibitors currently in trials are producing encouraging results in ALK-positive NSCLC,even in patients with acquired resistance to crizotinib. The success in identifying the ALK translocations and developing targeted drugs to exploit it is essential to maximize the efficacy of ALK inhibitors therapy for patients with lung cancer.